Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week phase 3 trial of flexible or fixed SIBA versus insulin glargine in type 2 diabetes mellitus
2008-005771-10Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec and insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change from baseline in HbA1c after 26 weeks of treatment, Non-inferiority of flexible-dose SIBA versus insulin glargine and 2 more. Started Jun 2009; status: completed.
02
Drugs
insulin degludecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005771-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005771-10.